This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
U.S. Stock Futures Rise on Strong Q2 Earnings
by Zacks Equity Research
Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.
Pre-markets Green on Strong Earnings Numbers
by Zacks Equity Research
Pre-markets Green on Strong Earnings Numbers.
CVS Health (CVS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 11.11% and 5.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Herbalife LTD. (HLF) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Herbalife LTD. (HLF) delivered earnings and revenue surprises of 52.38% and 7.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Aug 3
by Zacks Equity Research
MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.
CVS Health Q2 Preview: Can the Earnings Streak Continue?
by Derek Lewis
Bottom-line beats are the name of the game for CVS; the company hasn't reported quarterly EPS below the Zacks Consensus EPS Estimate since 2015.
Rite Aid (RAD) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Rite Aid (RAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $95.53, marking a -0.35% move from the previous day.
Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $94.06 in the latest trading session, marking a +0.93% move from the prior day.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance and Amazon have been highlighted in this Industry Outlook article.
2 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Challenges
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry is gaining from the growing demand for digital healthcare support. Industry players like CVS and WBA are likely to gain the most. However, reimbursement challenges are hurting the overall industry health.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $94.29, moving -1.13% from the previous trading session.
CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay
by Zacks Equity Research
CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.
Herbalife LTD. (HLF) Soars 15.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Herbalife LTD. (HLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Berkshire Hathaway, The Walt Disney, CVS Health, Citigroup and Canadian National Railway
by Zacks Equity Research
Berkshire Hathaway, The Walt Disney, CVS Health, Citigroup and Canadian National Railway are part of Zacks top Analyst Blog.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $94.71, moving +0.56% from the previous trading session.
Top Research Reports for Berkshire Hathaway, Walt Disney & CVS
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Walt Disney Company (DIS) and CVS Health Corporation (CVS).
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $92.53, moving -1.5% from the previous trading session.
Why CVS Health (CVS) Could Beat Earnings Estimates Again
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Moves -1.42%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $93.20 in the latest trading session, marking a -1.42% move from the prior day.
Here's Why Investors Should Retain CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.